To carry out their activities, Research Teams of the Frédéric Joliot Institute for Life Sciences have developed high-profile technological platforms in many areas : biomedical imaging, structural biology, metabolomics, High-Throughput screening, level 3 microbiological safety laboratory...
All the news of the Institute of life sciences Frédéric Joliot
The Service Hospitalier Frédéric Joliot (SHFJ), directed by Vincent Lebon, is a molecular and functional imaging center located on the Orsay hospital site. It ensures a medical service mission and a research and development mission which are mainly in the three following disciplines: oncology, neurology and pharmacology. This research aims to create new imaging tools to improve the diagnosis and evaluation of innovative therapies.
Researchers from the SHFJ and the DMTS have developed optimized radioligands for immunoPET imaging. The objective is to better predict the effectiveness of anti-PD1/anti-PDL1 immunotherapy used to fight certain cancers.
A team from BioMaps (SHFJ), in collaboration with several hospital groups, shows that hybrid PET/MRI imaging significantly improves the detection of epileptogenic foci and, consequently, the outcome of surgical treatment of epilepsy.
A joint team from GHU Paris and SHFJ shows the predictive value of PET imaging data of the Tau protein in the progression of Alzheimer's disease.
A collaboration between the SHFJ and the UMR-S 1144 (University of Paris) shows that the deleterious effect of the buprenorphine/benzodiazepine combination would result from the combined action of each drug on its target.
7T Sodium MRI may well prove increasingly useful in the study of physiological processes in inflammatory and neurodegenerative diseases and brain tumors. An example is a study on Alzheimer's disease, led by a NeuroSpin team.
Researchers at NeuroSpin have developed a deconvolution method to estimate from BOLD fMRI data the coupling between neuronal activity and blood flow, the characteristic signals of neuronal activity and the associated brain areas. The work was published in NeuroImage.
The international OpenGATE collaboration, involving the BioMaps laboratory(SHFJ), has demonstrated the value of the GATE numerical simulation platform in clinical use for cancer treatment planning using hadrontherapy.
CEA is a French government-funded technological research organisation in four main areas: low-carbon energies, defense and security, information technologies and health technologies. A prominent player in the European Research Area, it is involved in setting up collaborative projects with many partners around the world.